Breast cancer genetics

P01	Contribution of germline mutations in lysosomal storage disease-related genes contributes to breast cancer development Han-Byoel Lee, South Korea
P02	Multifocality in BRCA-associated breast cancer: A cross-sectional analysis Stuart Mcintosh, UK

Breast cancer screening

P03	Women informed to screen depending on measures of risk (WISDOM): A personalized breast cancer screening in a population based study Irene Acerbi, USA
P04	Has the transition to digital mammography in breast cancer screening resulted in real benefits? Rachel Farber, Australia
P05	Barriers and lessons learned after implementing coverage with evidence progression with private payers in a national, precision medicine breast screening trial Yash Huilgol, USA

Breast imaging

P06	Correlation of breast background parenchymal enhancement on MRI with morphophysiological parameters of breast and breast lesions Zehra Hilal Adibelli, Turkey
P07	Pure fibrocystic change diagnosed at MRI-guided vacuum-assisted breast biopsy: Imaging features and follow-up outcomes Shu-Tian Chen, USA
P08	A multi-center open-label parallel phase-2 clinical trial to evaluate the efficacy and safety of LuminoMarktm for localization in patients with non-palpable breast lesions Seung Ki Kim, South Korea
P09	Factors associated with MRI detection of occult lesions in newly diagnosed breast cancer Julie Lang, USA
P10	3D automatic density analysis device might be better for accurate breast density in Japanese women with breast cancer Misaki Matsuyanagi, Japan
P11	Magnetic resonance imaging features of pure sclerosing adenosis in the breast undergoing vacuum assisted breast core biopsy Satoko Okamoto, Japan
P12	Radial sclerosing lesions of the breast. A single-institution experience and literature review Nikolaos Salemis, Greece
P13	Unique characteristics of the breast density (cancer, benign disease, screening) in Japanese women are clarified by using VolparaTM Terumasa Sawada, Japan
P14	Utility of contralateral breast ultrasound in diagnosing synchronous breast cancer in newly diagnosed cancer patients Ying Ching Tan, Singapore

Breast reconstruction

P15	Outcomes and complications of immediate and delayed breast reconstruction Marwa Badawi, UK
P16	What should be used for lower pole coverage in immediate two-stage expander/implant breast reconstruction? A feasibility study Negin Sedaghat, Australia

DCIS

P17	Patient-centered initiatives to enhance recruitment to the COMET study Donna Pinto, USA

Endocrine resistance

P18	Response rate by geographic region in patients with hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer from the SOLAR-1 trial Ingrid Mayer, USA

Her2 positive breast cancer

P19	Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage ER+/HER2− breast cancer Javier Cortes, Spain
P20	Fluorescence in situ hybridization analysis of HER2 3+ breast cancer patients with neoadjuvant chemotherapy using pertuzumab and trastuzumab Choi Jin Hyuk, South Korea

Locoregional therapy

P21	A case of metaplastic breast carcinoma presenting as a bleeding breast mass Ma Corazon Cabanilla-Manuntag, Philippines
P22	Factors associated with false negative rate of sentinel lymph node biopsy in breast cancer patients Joyce Hazel Chua, Philippines
P23	Can we avoid axillary lymph node dissection (ALND) in patients with 1-2 positive sentinel/low axillary lymph nodes (SLN/LAS+) in the Indian setting? Asha Reddy, India
P24	Breast carcinoma with medullary features. A clinicopathologic study Nikolaos Salemis, Greece
P25	Adenoid cystic carcinoma of the breast Nikolaos Salemis, Greece
P26	Examination of the appropriate treatment for elderly breast cancer patients over 80 Shinichi Sekine, Japan
P27	Does metastatic inflammatory breast cancer have a worse prognosis after surgery? Yoko Takahashi, Japan

Molecular assays

P28	How patient advocates and researchers work together in PRECISION* to identify low-risk ductal carcinoma in situ (DCIS) that may not need aggressive treatment Deborah Collyar, USA
P29	Somatic mutation in breast cancer through next generation sequencing: A single institution experience Choi Jin Hyuk, South Korea

Neoadjuvant therapy

P30	A randomized controlled trial to compare the efficacy of hyperbaric oxygen along with neoadjuvant chemotherapy with neoadjuvant chemotherapy alone for carcinoma breast Rijuta Aphale, India
P31	A call to change world guidelines: Medical therapy 1st Maria Antonia Coccia-Portugal, South Africa
P32	Risk of ipsilateral breast tumor recurrence in breast conserving surgery after neoadjuvant therapy Se Young Kim, South Korea
P33	Radiologic complete response after neoadjuvant chemotherapy in advanced breast cancer can predict survival outcome, but not pathologic complete response Jinsun Woo, South Korea

Oncoplastic surgery

P34	Periaeolar round block technique of breast conserving surgery: A single institution experience Choi Jin Hyuk, South Korea

Prevention

P35	Elevated levels of serum tumor maker p53 is a prognostic paramator and a monitoring biomaker for patients who had undergone surgical resection in breast cancer Mie Arai, Japan
P36	Development and pilot of a personalized, online prevention decision aid for breast cancer risk reduction in the WISDOM study Yash Huilgol, USA

Radiotherapy

P37	Comparison of ESTRO and RTOG contouring guidelines for target volume delineation in early stage breast cancers Tony Mathew, Australia
P38	A dosimetric comparison of tangent FIF, VMAT and hybrid-VMAT for chest wall radiation therapy with AeroForm tissue Charlene Tan, USA
P39	A practical formula to guide partial inflation of contralateral tissue expanders for optimal post-mastectomy radiation Charlene Tan, USA
P40	Preliminary results of hypofractionated post-mastectomy radiotherapy (PMRT-HF): Dosimetry, loco-regional control and toxicity Ana Vasconcelos, Portugal

Symptom management

P41	Case control study; seroma control using axillary exclusion technique Marwa Badawi, UK
P42	Case report: Fibroadenoma of the breast in identical twin Ahmed Shalaby, UK

Triple negative breast cancer

P43	Targeting semaphorin 3C in triple negative breast cancer induces apoptosis and chemo-sensitivity Satyam Bhasin, Canada
P44	Radiation stimulates the invasiveness and lung metastasis development in a mouse model of triple-negative breast cancer Benoit Paquette, Canada